[go: up one dir, main page]

DE60020812D1 - Heteroaryl-substituierte chinolin-2-on derivate verwendbar als antikrebsmittel - Google Patents

Heteroaryl-substituierte chinolin-2-on derivate verwendbar als antikrebsmittel

Info

Publication number
DE60020812D1
DE60020812D1 DE60020812T DE60020812T DE60020812D1 DE 60020812 D1 DE60020812 D1 DE 60020812D1 DE 60020812 T DE60020812 T DE 60020812T DE 60020812 T DE60020812 T DE 60020812T DE 60020812 D1 DE60020812 D1 DE 60020812D1
Authority
DE
Germany
Prior art keywords
chinolin
heteroaryl
substituted
derivatives use
anticrobial
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60020812T
Other languages
English (en)
Other versions
DE60020812T2 (de
Inventor
Bingwei Vera Yang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
Original Assignee
Pfizer Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc filed Critical Pfizer Products Inc
Application granted granted Critical
Publication of DE60020812D1 publication Critical patent/DE60020812D1/de
Publication of DE60020812T2 publication Critical patent/DE60020812T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DE60020812T 1999-02-11 2000-02-04 Heteroaryl-substituierte chinolin-2-on derivate verwendbar als antikrebsmittel Expired - Lifetime DE60020812T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11970299P 1999-02-11 1999-02-11
US119702P 1999-02-11
PCT/IB2000/000121 WO2000047574A1 (en) 1999-02-11 2000-02-04 Heteroaryl-substituted quinolin-2-one derivatives useful as anticancer agents

Publications (2)

Publication Number Publication Date
DE60020812D1 true DE60020812D1 (de) 2005-07-21
DE60020812T2 DE60020812T2 (de) 2006-05-04

Family

ID=22385869

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60020812T Expired - Lifetime DE60020812T2 (de) 1999-02-11 2000-02-04 Heteroaryl-substituierte chinolin-2-on derivate verwendbar als antikrebsmittel

Country Status (39)

Country Link
US (3) US6258824B1 (de)
EP (1) EP1150973B1 (de)
JP (3) JP4090200B2 (de)
KR (1) KR20010102073A (de)
CN (1) CN1340051A (de)
AP (1) AP2001002241A0 (de)
AR (1) AR028985A1 (de)
AT (1) ATE297916T1 (de)
AU (1) AU2124800A (de)
BG (1) BG105860A (de)
BR (1) BR0008202A (de)
CA (1) CA2362394C (de)
CO (1) CO5140097A1 (de)
CZ (1) CZ20012910A3 (de)
DE (1) DE60020812T2 (de)
DZ (1) DZ3009A1 (de)
EA (1) EA200100766A1 (de)
EE (1) EE200100425A (de)
ES (1) ES2243228T3 (de)
GT (1) GT200000014A (de)
HK (1) HK1042096A1 (de)
HN (1) HN2000000019A (de)
HR (1) HRP20010574A2 (de)
HU (1) HUP0105231A3 (de)
ID (1) ID29584A (de)
IL (1) IL144307A0 (de)
IS (1) IS5997A (de)
MA (1) MA26718A1 (de)
NO (1) NO20013909L (de)
OA (1) OA11833A (de)
PA (1) PA8490601A1 (de)
PE (1) PE20001464A1 (de)
PL (1) PL349839A1 (de)
SK (1) SK11002001A3 (de)
SV (1) SV2001000020A (de)
TN (1) TNSN00028A1 (de)
TR (2) TR200201296T2 (de)
WO (1) WO2000047574A1 (de)
ZA (1) ZA200106520B (de)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9911861A (pt) * 1998-07-06 2001-03-20 Janssen Pharmaceutica Nv Inibidores de farnesil proteìna transferase com as propriedades radiossensibilizadoras in vivo
HK1042096A1 (zh) * 1999-02-11 2002-08-02 辉瑞产品公司 可用作抗癌剂的杂芳基取代的喹啉-2-酮衍生物
AU781986B2 (en) * 1999-11-05 2005-06-23 Cytovia, Inc. Substituted 4H-chromene and analogs as activators of caspases and inducers of apoptosis and the use thereof
TR200400342T4 (tr) * 1999-11-30 2004-03-22 Pfizer Products Inc. Farnezil protein transferazı önlemek için kinolin türevleri.
HN2000000266A (es) * 2000-01-21 2001-05-21 Pfizer Prod Inc Compuesto anticanceroso y metodo de separacion de enantiomeros util para sintetizar dicho compuesto.
WO2001054688A1 (en) * 2000-01-28 2001-08-02 Merck & Co., Inc. Treatment or prevention of prostate cancer with a cox-2 selective inhibiting drug
JO2361B1 (en) 2000-06-22 2006-12-12 جانسين فارماسيوتيكا ان. في Enaniumer 1,2-anylated quinoline inhibitor for the transporter - farnesyl
EP1170011A1 (de) * 2000-07-06 2002-01-09 Boehringer Ingelheim International GmbH Neue Verwendung von Inhibitoren der Rezeptoren des epidermalen Wachstumsfaktors
JP4974439B2 (ja) * 2000-09-25 2012-07-11 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ファルネシルトランスフェラーゼを阻害する６−ヘテロシクリルメチルキノリノン誘導体
AU2001293829A1 (en) 2000-09-25 2002-04-02 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting 6-((substituted phenyl)methyl)-quinoline and quinazoline derivatives
ATE321038T1 (de) 2000-09-25 2006-04-15 Janssen Pharmaceutica Nv Chinolin- und chinazolinderivate und deren verwendung als farnesyl transferase inhibitoren
US7196094B2 (en) 2000-09-25 2007-03-27 Janssen Pharmaceutica, N.V. Farnesyl transferase inhibiting 6-heterocyclylmethyl quinoline and quinazoline derivatives
EE05195B1 (et) * 2000-10-02 2009-08-17 Janssen Pharmaceutica N.V. Kinoliini ja kinolinooni derivaadid glutamaatretseptori antagonistidena, nende saamine ja kasutamine ravimite valmistamiseks ning neid sisaldav farmatseutiline kompositsioon
ES2328225T3 (es) 2000-11-21 2009-11-11 Janssen Pharmaceutica Nv Derivados benzoheterociclicos inhibidores de la farnesil-transferasa.
PT1351954E (pt) * 2000-12-27 2006-09-29 Janssen Pharmaceutica Nv Derivados 4-heterociclil-quinolina e quinazolina inibidores da farnesil-transferase
JP4351445B2 (ja) 2000-12-27 2009-10-28 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ファルネシルトランスフェラーゼを阻害する４−置換−キノリンおよびキナゾリン誘導体
US7015328B2 (en) 2001-05-16 2006-03-21 Cytovia, Inc. Substituted coumarins and quinolines and analogs as activators of caspases and inducers of apoptosis and the use thereof
WO2002092594A1 (en) * 2001-05-16 2002-11-21 Cytovia, Inc. Substituted 4h-chromenes and analogs as activators of caspases and inducers of apoptosis and the use thereof
US6858607B1 (en) 2001-05-16 2005-02-22 Cytovia, Inc. 7,8-fused 4H-chromene and analogs as activators of caspases and inducers of apoptosis and the use thereof
US20030139332A1 (en) * 2001-07-09 2003-07-24 The Regents Of The University Of California Use of matrix metalloproteinase inhibitors to mitigate nerve damage
EP1458720B1 (de) 2001-12-19 2009-03-18 Janssen Pharmaceutica N.V. Durch c-verbundene imidazole substituierte 1,8-annellierten chinolon-derivate als farnesyl transferase inhibitoren
JP4450628B2 (ja) 2002-03-22 2010-04-14 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ファルネシルトランスフェラーゼインヒビターとして使用するためのベンジルイミダゾリル置換２−キノリンおよびキナゾリン誘導体
CA2479109C (en) * 2002-03-29 2011-08-02 Janssen Pharmaceutica N.V. Radiolabelled quinoline and quinolinone derivatives and their use as metabotropic glutamate receptor ligands
ATE336496T1 (de) 2002-04-15 2006-09-15 Janssen Pharmaceutica Nv Farnesyl transferase hemmende tricyclische quinazolinederivate substitutiert mit kohlenstoff-gebundenen imidazolen oder triazolen
JP2005531566A (ja) 2002-05-16 2005-10-20 サイトビア インコーポレイティッド カスパーゼ活性化剤およびアポトーシス誘導物質としての置換４−アリール−４ｈ−ピロロ［２，３−ｈ］クロメンおよび類似体ならびにそれらの使用
US7476741B2 (en) 2002-05-16 2009-01-13 Cytovia, Inc. Substituted 4H-chromens, 2H-chromenes, chromans and analogs as activators of caspases and inducers of apoptosis and the use thereof
US20040186160A1 (en) * 2002-12-13 2004-09-23 Sugen, Inc. Hexahydro-cyclohepta-pyrrole oxindole as potent kinase inhibitors
EA008501B1 (ru) * 2002-12-19 2007-06-29 Пфайзер Инк. 2-(1н-индазол-6-иламино)бензамидные соединения как ингибиторы протеинкиназ, полезные для лечения офтальмологических заболеваний
CN103265477B (zh) 2003-02-26 2017-01-11 苏根公司 作为蛋白激酶抑制剂的氨基杂芳基化合物
TW200504057A (en) * 2003-02-27 2005-02-01 Chugai Pharmaceutical Co Ltd Benzothiophene derivative
EP1660087A2 (de) * 2003-07-22 2006-05-31 Janssen Pharmaceutica N.V. Chinolinon-derivate als c-fms-kinase-hemmer
CA2546727C (en) 2003-11-20 2012-10-02 Children's Hospital Medical Center Gtpase inhibitors and methods of use
US20050272722A1 (en) * 2004-03-18 2005-12-08 The Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies
US20050288298A1 (en) * 2004-03-18 2005-12-29 The Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies
US20050277629A1 (en) * 2004-03-18 2005-12-15 The Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies (Lansbury)
US20070293539A1 (en) * 2004-03-18 2007-12-20 Lansbury Peter T Methods for the treatment of synucleinopathies
US20060106060A1 (en) * 2004-03-18 2006-05-18 The Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies (Lansbury)
EP1740184A1 (de) * 2004-03-30 2007-01-10 Pfizer Products Incorporated Kombinationen von signalübertragungshemmern
JP2008510792A (ja) * 2004-08-26 2008-04-10 ファイザー・インク タンパク質チロシンキナーゼ阻害剤としてのアミノヘテロアリール化合物
KR100859891B1 (ko) 2004-08-26 2008-09-23 화이자 인코포레이티드 단백질 키나제 억제제로서 거울상이성질체적으로 순수한아미노헤테로아릴 화합물
ES2355923T3 (es) * 2004-08-26 2011-04-01 Pfizer, Inc. Compuestos de aminoheteroarilo sustituidos con pirazol como inhibidores de proteina quinasa.
EP1807426A2 (de) * 2004-10-07 2007-07-18 Cytovia, Inc. Substituierte n-aryl-1h-pyrazolo[3,4-b]chinolin-4-amine und deren analoge als aktivatoren von caspasen und induktoren von apoptose
US7826982B2 (en) 2005-07-29 2010-11-02 Children's Hospital Medical Center Method of identifying inhibitors using a 3-D structure of RAC-1 GTPASE
UA94060C2 (ru) 2005-09-07 2011-04-11 Эмджен Фримонт Инк. Моноклональное антитело, которое специфически связывает alk-1
CA2623125A1 (en) 2005-09-20 2007-03-29 Osi Pharmaceuticals, Inc. Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
JP2009521470A (ja) * 2005-12-23 2009-06-04 リンク メディシン コーポレイション シヌクレイン障害の治療
TW200812615A (en) 2006-03-22 2008-03-16 Hoffmann La Roche Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
BRPI0711358A2 (pt) 2006-05-09 2011-09-27 Pfizer Prod Inc derivados do ácido cicloalquilamino e suas composições farmacêuticas
EP2441472B1 (de) 2006-08-21 2015-06-10 F. Hoffmann-La Roche AG Tumortherapie mit einem Anti-VEGF-Antikörper
CA2687973C (en) * 2007-05-23 2015-04-07 Allergan, Inc. ((bicylicheteroaryl) imidazolyl)methylheteroaryl compounds as adrenergic receptor agonists
DK2155733T3 (da) * 2007-05-23 2012-10-29 Allergan Inc Cykliske lactamer til behandling af glaukom eller forhøjet intraokulært tryk
US8129356B2 (en) * 2007-10-01 2012-03-06 Vanderbilt University Bmx mediated signal transduction in irradiated vascular endothelium
WO2009151683A2 (en) * 2008-03-12 2009-12-17 Link Medicine Corporation Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications
DE102008022221A1 (de) * 2008-05-06 2009-11-12 Universität des Saarlandes Inhibitoren der humanen Aldosteronsynthase CYP11B2
US20110060005A1 (en) * 2008-11-13 2011-03-10 Link Medicine Corporation Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
CA2743717A1 (en) * 2008-11-13 2010-05-20 Link Medicine Corporation Azaquinolinone derivatives and uses thereof
US20100331363A1 (en) * 2008-11-13 2010-12-30 Link Medicine Corporation Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
SG172857A1 (en) * 2009-02-09 2011-08-29 Supergen Inc Pyrrolopyrimidinyl axl kinase inhibitors
US20120189641A1 (en) 2009-02-25 2012-07-26 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
US20110171124A1 (en) 2009-02-26 2011-07-14 Osi Pharmaceuticals, Inc. In situ methods for monitoring the EMT status of tumor cells in vivo
US20100222381A1 (en) 2009-02-27 2010-09-02 Hariprasad Vankayalapati Cyclopentathiophene/cyclohexathiophene DNA methyltransferase inhibitors
WO2010099138A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
JP2012519282A (ja) 2009-02-27 2012-08-23 オーエスアイ・ファーマシューティカルズ，エルエルシー 間葉様腫瘍細胞またはその生成を阻害する薬剤を同定するための方法
EP2401614A1 (de) 2009-02-27 2012-01-04 OSI Pharmaceuticals, LLC Verfahren zur identifizierung von mesenchymähnlichen tumorzellen oder deren bildung hemmenden stoffen
EP2519826A2 (de) 2010-03-03 2012-11-07 OSI Pharmaceuticals, LLC Biologische marker als prädiktoren der antikrebsreaktion auf insulinähnlichen wachstumsfaktor-1-rezeptor-kinaseinhibitoren
US20110217309A1 (en) 2010-03-03 2011-09-08 Buck Elizabeth A Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
WO2012116040A1 (en) 2011-02-22 2012-08-30 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma
WO2012149014A1 (en) 2011-04-25 2012-11-01 OSI Pharmaceuticals, LLC Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
PT3409278T (pt) 2011-07-21 2020-12-18 Sumitomo Dainippon Pharma Oncology Inc Inibidores de proteína cinase heterocíclicos
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
WO2013166043A1 (en) 2012-05-02 2013-11-07 Children's Hospital Medical Center Rejuvenation of precursor cells
BR112015008515A2 (pt) 2012-10-16 2017-07-04 Janssen Pharmaceutica Nv moduladores de ror t de quinolinila ligada à heteroarila
ES2628365T3 (es) 2012-10-16 2017-08-02 Janssen Pharmaceutica N.V. Moduladores de quinolinilo unidos a fenilo de ROR-GAMA-T
PE20150778A1 (es) 2012-10-16 2015-05-23 Janssen Pharmaceutica Nv Moduladores de quinolinilo unidos a metileno de ror-gamma-t
US9260426B2 (en) 2012-12-14 2016-02-16 Arrien Pharmaceuticals Llc Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors
AR094403A1 (es) 2013-01-11 2015-07-29 Hoffmann La Roche Terapia de combinación de anticuerpos anti-her3
DK2970205T3 (da) 2013-03-14 2019-07-29 Tolero Pharmaceuticals Inc JAK2- og ALK2-inhibitorer og fremgangsmåder til anvendelse deraf
US9206188B2 (en) 2013-04-18 2015-12-08 Arrien Pharmaceuticals Llc Substituted pyrrolo[2,3-b]pyridines as ITK and JAK inhibitors
US9403816B2 (en) 2013-10-15 2016-08-02 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of RORγt
US9328095B2 (en) 2013-10-15 2016-05-03 Janssen Pharmaceutica Nv Heteroaryl linked quinolinyl modulators of RORgammat
US9284308B2 (en) 2013-10-15 2016-03-15 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of RORγt
US9221804B2 (en) 2013-10-15 2015-12-29 Janssen Pharmaceutica Nv Secondary alcohol quinolinyl modulators of RORγt
CA2926339A1 (en) 2013-10-15 2015-04-23 Janssen Pharmaceutica Nv Alkyl linked quinolinyl modulators of roryt
WO2015057626A1 (en) 2013-10-15 2015-04-23 Janssen Pharmaceutica Nv QUINOLINYL MODULATORS OF RORyT
US10555941B2 (en) 2013-10-15 2020-02-11 Janssen Pharmaceutica Nv Alkyl linked quinolinyl modulators of RORγt
US10028503B2 (en) 2014-06-18 2018-07-24 Children's Hospital Medical Center Platelet storage methods and compositions for same
WO2017096165A1 (en) 2015-12-03 2017-06-08 Agios Pharmaceuticals, Inc. Mat2a inhibitors for treating mtap null cancer
CN108003150A (zh) * 2016-10-31 2018-05-08 河南工业大学 4-杂芳基喹啉酮衍生物的制备方法及其应用
KR20210038906A (ko) 2018-07-26 2021-04-08 스미토모 다이니폰 파마 온콜로지, 인크. 비정상적 acvr1 발현과 연관된 질환을 치료하는 방법 및 그에 사용하기 위한 acvr1 억제제
AU2020221247B2 (en) 2019-02-12 2024-12-12 Sumitomo Pharma America, Inc. Formulations comprising heterocyclic protein kinase inhibitors
CN114450027A (zh) 2019-08-16 2022-05-06 儿童医院医疗中心 用cdc42特异性抑制剂治疗受试者的方法
WO2021155006A1 (en) 2020-01-31 2021-08-05 Les Laboratoires Servier Sas Inhibitors of cyclin-dependent kinases and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2732531A1 (de) * 1977-07-19 1979-02-01 Hoechst Ag Imidazolcarbonsaeuren und deren derivate
US4835154A (en) * 1987-06-01 1989-05-30 Smithkline Beckman Corporation 1-aralykyl-5-piperazinylmethyl-2-mercaptoimidazoles and 2-alkylthioimidazoles and their use as dopamine-βhydroxylase inhibitors
US5053543A (en) * 1990-11-28 1991-10-01 Glaxo Inc. Synthesis of 2-aminobenzophenones
US5136085A (en) * 1990-11-28 1992-08-04 Glaxo Inc. Synthesis of 2-aminobenzophenones
TW349948B (en) 1995-10-31 1999-01-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 2-quinolone derivatives
SI0865440T1 (en) * 1995-12-08 2002-08-31 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibiting (imidazol-5-yl)methyl-2-quinolinone derivatives
IL133212A (en) * 1997-06-02 2005-12-18 Janssen Pharmaceutica Nv History of use (imidazolil-5-yl) methyl-2-quinolinone that act as culture inhibitors of smooth muscle cells
WO2000012499A1 (en) 1998-08-27 2000-03-09 Pfizer Products Inc. Alkynyl-substituted quinolin-2-one derivatives useful as anticancer agents
HK1042096A1 (zh) * 1999-02-11 2002-08-02 辉瑞产品公司 可用作抗癌剂的杂芳基取代的喹啉-2-酮衍生物

Also Published As

Publication number Publication date
KR20010102073A (ko) 2001-11-15
US6710209B2 (en) 2004-03-23
SK11002001A3 (sk) 2002-05-09
JP4216740B2 (ja) 2009-01-28
CA2362394A1 (en) 2000-08-17
EA200100766A1 (ru) 2002-02-28
OA11833A (en) 2005-08-23
AP2001002241A0 (en) 2001-09-30
IS5997A (is) 2001-07-10
CZ20012910A3 (cs) 2002-02-13
PA8490601A1 (es) 2002-07-30
BR0008202A (pt) 2002-02-19
CO5140097A1 (es) 2002-03-22
DZ3009A1 (fr) 2004-03-27
EP1150973B1 (de) 2005-06-15
HN2000000019A (es) 2001-07-30
NO20013909D0 (no) 2001-08-10
EP1150973A1 (de) 2001-11-07
EE200100425A (et) 2002-12-16
BG105860A (en) 2002-03-29
ID29584A (id) 2001-09-06
JP2005002124A (ja) 2005-01-06
US6258824B1 (en) 2001-07-10
DE60020812T2 (de) 2006-05-04
AR028985A1 (es) 2003-06-04
ATE297916T1 (de) 2005-07-15
HUP0105231A3 (en) 2003-01-28
HK1042096A1 (zh) 2002-08-02
GT200000014A (es) 2001-08-03
CA2362394C (en) 2006-01-17
HUP0105231A2 (hu) 2002-04-29
TNSN00028A1 (fr) 2005-11-10
US6388092B2 (en) 2002-05-14
JP4090200B2 (ja) 2008-05-28
SV2001000020A (es) 2001-11-08
ES2243228T3 (es) 2005-12-01
WO2000047574A1 (en) 2000-08-17
PE20001464A1 (es) 2000-12-20
PL349839A1 (en) 2002-09-23
CN1340051A (zh) 2002-03-13
HRP20010574A2 (en) 2002-12-31
TR200201296T2 (tr) 2002-07-22
ZA200106520B (en) 2002-08-26
JP2002536444A (ja) 2002-10-29
US20020120145A1 (en) 2002-08-29
US20020019530A1 (en) 2002-02-14
TR200201297T2 (tr) 2002-06-21
AU2124800A (en) 2000-08-29
NO20013909L (no) 2001-10-08
JP2004182741A (ja) 2004-07-02
MA26718A1 (fr) 2004-12-20
IL144307A0 (en) 2002-05-23

Similar Documents

Publication Publication Date Title
DE60020812D1 (de) Heteroaryl-substituierte chinolin-2-on derivate verwendbar als antikrebsmittel
DE60032601D1 (de) Als antikrebsmittel verwendbare heterocyklische derivate
DE69920009D1 (de) Isothiazole derivate verwendbar als antikrebsmittel
ATE359275T1 (de) Substituierte bizyclische derivate verwendbar als antitumor mittel
DE60009147D1 (de) Admantan derivate
ID29550A (id) Quinolinakarboksamida sebagai agen-agen antivirus
DE69930518D1 (de) Als antikrebsmittel verwendbare alkinyl-substituierte chinolin-2-on-derivate
ATE293618T1 (de) 4, 5, 6, 7-tetrahydroindazolderivate als antitumormittel
DE60010448D1 (de) Amid-derivate
ATE263748T1 (de) Admantan-derivate
ATE273962T1 (de) 5-phenyl-pyrimidine derivate
DE50010060D1 (de) Thiazolylamid-derivate
PT1235558E (pt) Agentes terapeuticos
ATE273980T1 (de) 6-phenylpyrrolopyrimidindion derivate
ATE257148T1 (de) Propargyletherderivate
ATE273272T1 (de) Mevinolinderivate
ATE254621T1 (de) Thienoisoxazolyl- und thienylpyrazolyl-phenoxy substituierte propyl derivate als d4 antagonisten
ATE374747T1 (de) Monofluoralkylderivate
ATE317389T1 (de) 4-phenyl-pyrimidine derivate
DE50011908D1 (de) 16-hydroxyestratriene als selektiv wirksame estrogene
ATE293592T1 (de) Resorcinderivate
ATE254598T1 (de) 4-hydroxybiphenylhydrazid-derivate
DE60003072D1 (de) Thiazolidindion-derivate als antidiabetika
TR200002831A3 (tr) Kinolin-4-Il türevleri I
ATE496034T1 (de) Phtalazinon derivate

Legal Events

Date Code Title Description
8364 No opposition during term of opposition